文献速递前列腺癌

PEACE V-STORM:寡复发淋巴结前列腺癌转移的挽救治疗——随机2期试验的急性毒性

PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
PubMed 文献 · Eur Urol Oncol · 2023-10-09

PEACE V-STORM是一项国际2期开放标签随机优效性试验,纳入196例PET检测的盆腔淋巴结寡复发(≤5枚)前列腺癌患者,1:1随机分为A组(转移灶定向治疗+6个月雄激素剥夺治疗)与B组(选择性盆腔淋巴结放疗25×1.8 Gy+转移灶定向治疗+6个月雄激素剥夺治疗)。两组急性≥2级胃肠道毒性分别为3%与4%(p=0.11),≥2级泌尿生殖毒性分别为8%与13%(p=0.95),生活质量各子领域评分较基线临床显著下降的患者比例无显著差异。

要点

  • 两组急性≥2级胃肠道毒性:A组3% vs B组4%(p=0.11)。
  • 两组急性≥2级泌尿生殖毒性:A组8% vs B组13%(p=0.95)。
  • 生活质量各子领域评分较基线临床显著下降的患者比例两组无显著差异。

核心结论

  • 转移灶定向治疗与选择性盆腔淋巴结放疗在 worst grade ≥2 急性胃肠道或泌尿生殖毒性及生活质量子领域方面未见有临床意义的差异。

研究设计与样本

  • 国际、2期、开放标签、随机、优效性试验(ClinicalTrials.gov标识符NCT03569241)。
  • 纳入PET检测的盆腔淋巴结寡复发(≤5枚)且既往接受前列腺癌根治性局部治疗的患者,1:1随机分为A组(转移灶定向治疗+6个月雄激素剥夺治疗)与B组(选择性盆腔淋巴结放疗25×1.8 Gy+转移灶定向治疗+6个月雄激素剥夺治疗)。
  • 2018年6月至2021年4月共随机分配196例患者;分配至转移灶定向治疗的99例中97例、分配至选择性盆腔淋巴结放疗的97例中93例接受了符合方案的治疗。

主要发现

  • 急性≥2级胃肠道毒性:转移灶定向治疗组3例(3%) vs 选择性盆腔淋巴结放疗组4例(4%)(p=0.11)。
  • 急性≥2级泌尿生殖毒性:转移灶定向治疗组8例(8%) vs 选择性盆腔淋巴结放疗组12例(13%)(p=0.95)。
  • 两组在任何子领域评分较基线临床显著下降的患者比例均无显著差异。

关键数值与推荐

  • 急性毒性定义为治疗3个月内最差等级≥2级的常见不良事件评价标准v4.0胃肠道或泌尿生殖毒性。
  • 采用卡方检验比较两组毒性。
  • 采用欧洲癌症研究与治疗组织QLQ C30和PR25问卷比较生活质量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment recommendations for patients with limited nodal recurrences are lacking, and different locoregional treatment approaches are currently being used. OBJECTIVE: The aim of this trial is to compare metastasis-directed therapy (MDT) with or without elective nodal pelvic radiotherapy (ENRT). DESIGN, SETTING, AND PARTICIPANTS: PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) is an international, phase 2, open-label, randomized, superiority trial (ClinicalTrials.gov identifier: NCT03569241). Patients diagnosed with positron emission tomography-detected pelvic nodal oligorecurrence (five or fewer nodes) following radical local treatment for prostate cancer were randomized in a 1:1 ratio between arm A (MDT and 6 mo of androgen deprivation therapy [ADT]) and arm B (ENRT [25 × 1.8 Gy] with MDT and 6 mo of ADT). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We report the secondary endpoint acute toxicity, defined as worst grade ≥2 Common Terminology Criteria for Adverse Events v4.0 gastrointestinal (GI) or genitourinary (GU) toxicity within 3 mo of treatment. The chi-square test was used to compare toxicity between treatment arms. We also compare the quality of life (QoL) using the European Organisation for Research and Treatment of Cancer QLQ C30 and PR25 questionnaires. RESULTS AND LIMITATIONS: Between June 2018 and April 2021, 196 patients were assigned randomly to MDT or ENRT. Ninety-seven of 99 patients allocated to MDT and 93 of 97 allocated to ENRT received per-protocol treatment. Worst acute GI toxicity proportions were as follows: grade ≥2 events in three (3%) in the MDT group versus four (4%) in the ENRT group (p = 0.11). Worst acute GU toxicity proportions were as follows: grade ≥2 events in eight (8%) in the MDT group versus 12 (13%) in the ENRT group (p = 0.95). We observed no significant difference between the study groups in the proportion of patients with a clinically significant QoL reduction from baseline for any subdomain score area. CONCLUSIONS: No clinically meaningful differences were observed in worst grade ≥2 acute GI or GU toxicity or in QoL subdomains between MDT and ENRT. PATIENT SUMMARY: We found no evidence of differential acute bowel or urinary side effects using metastasis-directed therapy and elective nodal radiotherapy for the treatment of patients with a pelvic lymph node recurrence.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ost P, Siva S, Brabrand S, et al. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. 2023. PMID: 37821242. doi:10.1016/j.euo.2023.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。